Close menu




October 20th, 2021 | 12:10 CEST

Formycon, Memiontec, Synlab - Act before it is too late!

  • Investments
Photo credits: pixabay.com

When an unpredictable event occurs, humanity sees how powerless it is in the face of it. We saw this in the spring of last year with the outbreak of the Corona pandemic. Only since the approval of various vaccines has a normalization taken place. However, further, foreseeable problems are coming our way. According to expert forecasts, water demand will exceed supply by 40% as early as 2030. Some companies sense an opportunity to profit from the water shortage through novel technologies.

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: FORMYCON AG | DE000A1EWVY8 , Memiontec Holdings Limited | SGXE56008290 , SYNLAB AG | DE000A2TSL71

Table of contents:


    Memiontec - Green-tech for decades

    The earth is covered mainly with water, accounting for 71% of the total, while only 29% percent of the earth's surface consists of landmass. Of the total water volume amounting to 1,332 million cubic kilometers, the much higher part of 97% is saltwater. Of the 3% of potable freshwater, in turn, only about one-third is accessible for human use, as the largest amount is located in high mountains and at both poles. Due to the growing world population and global warming, water is becoming increasingly scarce and precious.

    The Singapore-based Company Memiontec has been developing complete water and wastewater management solutions in China, Indonesia, and Singapore's city-state for 2 decades. The Company's clientele includes the public sector, such as municipalities and cities and private industrial companies. With a 4-pillar model, Memiontec covers the entire value chain of water management, which brings the Company enormous economies of scale.

    The provision of complete solutions, including maintenance contracts and the sale of modular and customized systems and equipment, are the prerequisites for the joint ventures founded with partners, which operate under the segments "Build-Own-Operate-Transfer" (BOOT) and "Transfer-Own-Operate-Transfer" (TOOT). Here, long-term contracts are concluded, usually for 25 years, and investments are made to maintain water treatment infrastructures. Memiontec then receives recurring payments through the supply and sale of treated water.

    A total of three of these projects exist currently, with a significant expansion planned for the future. Memiontec is also looking to grow through acquisitions and mergers in neighboring Asian countries. Recently, three orders with a total order value of the equivalent of EUR 51 million were announced. The Company is attractive in the long term and should continue to benefit from the water scarcity issue.

    Formycon - Important cooperation agreement

    The Corona pandemic produced several winners. Among them are vaccine producers and Formycon AG, one of the leading developers of high-quality biopharmaceutical follow-on products, or so-called biosimilars. With FYB207, the Munich-based Company has an ACE2 immunoglobulin fusion protein in the preclinical stage that has shown efficient in vitro neutralization of SARS-CoV-2 and its variants. SARS-CoV-2 and other coronaviruses utilize the ACE2 protein on the surface of human cells as a receptor for cell infection. Formycon has developed proprietary technology for human ACE2 immunoglobulin fusion proteins and created the innovative SARS-CoV-2 entry blocker FYB207. It effectively prevents cell infection and shows high protection against coronavirus escape mutations in cell cultures.

    A collaboration and license agreement for the development and commercialization of FYB207 with SCG Cell Therapy has been announced. Under the agreement, SCG gains access to Formycon's ACE2 fusion protein technology and acquires an exclusive license to develop, manufacture and commercialize FYB207 in the Asia-Pacific region, excluding Japan. In doing so, Formycon is eligible for potential development, regulatory and sales-related milestone payments of up to EUR 63.5 million, as well as royalties in the low double-digit percentage range on net sales. Formycon shares were able to form a bottom in the EUR 50 range. Concerning further corona research, the Company is promising.

    Synlab - Analysts cheer

    Also thrust into the spotlight by Corona is laboratory chain Synlab. The diagnostics service provider's test kits are used in schools in Germany, Switzerland and Frankfurt. With SARS-CoV-2 testing activity from July to September exceeding expectations, driven by the development of the Delta variant, full-year forecasts have been raised significantly.

    The Munich-based Company is now planning sales of EUR 3.5 billion. EBITDA is expected to reach the sound barrier of EUR 1 billion, compared to the previously estimated EUR 920 million. Following Synlab's forecast increases, several positive analyst voices were heard. Kepler Chevreux, Deutsche Bank, Jefferies, and Goldman Sachs all rate the stock as a "buy".


    The Corona pandemic hit humanity hard, as it was unprepared without vaccines and medication. The rapid development has benefited not only vaccine manufacturers but also companies such as Formycon and Synlab. Water scarcity is likely to be another problem in the coming years. Memiontec offers complete solutions for the water industry and should therefore profit in the long term.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by André Will-Laudien on January 31st, 2023 | 14:50 CET

    E-mobility 2023: The Tesla hunters are coming! BYD, Lucid Motors, Tocvan Ventures. Will the Varta share now also fly?

    • Mining
    • Gold
    • Electromobility
    • Investments

    It Is hard to believe! The Tesla share is once again making a name for itself. Analysts went into the presentation of the annual figures with cautious expectations because there were many negative rumors surrounding Elon Musk's electronics company: Fewer sales? Cars on stockpile? Again, it came as no one had expected it. Elon Musk delivered and simultaneously mocked all the shorties who wanted to push his stock below USD 100 at the turn of the year. This gambit went badly wrong because Tesla was able to deliver even better figures than expected, and there was no stopping the share. With plus 70% in only 4 weeks, the Tesla share belongs to the shooting stars since the turn of the year - the short sellers must have lost their desire completely. But the variety of interesting shares is significant. Where are the opportunities for e-investors lurking?

    Read

    Commented by Nico Popp on January 31st, 2023 | 14:33 CET

    This new project changes everything: Deutsche Bank, Aspermont, Alibaba

    • Digitization
    • Innovations
    • Technology
    • Investments

    When processes go digital, great opportunities arise: automation and scaling can ensure growth and turn established business models into high-flyers. But which companies should investors actively support in their transformation? Where is there real potential for investors, and where are companies just spreading buzzwords? We highlight three stocks for you.

    Read

    Commented by André Will-Laudien on January 30th, 2023 | 09:13 CET

    Mega biotech rally 2023! Defence Therapeutics, Bayer, BioNTech, Morphosys - Where to put the money?

    • Biotechnology
    • Cancer
    • Covid19
    • Investments

    Who would have thought it? Since the beginning of the year, the stock markets have been jubilant despite difficult predictions about the economic trend in 2023. High inflation and rising interest rates are not a good breeding ground for the popular biotech stocks because they have to constantly refinance their research expenses. As the risk fee is readjusted as costs rise, investors demand higher premiums for providing money. However, some biotech stocks have taken off since the beginning of the year despite adverse conditions. What is their secret?

    Read